胰高血糖素样肽-1受体激动剂与关节置换术后再入院及术后并发症:系统评价与Meta分析
该系统评价与Meta分析纳入8项回顾性队列研究、共76091例全髋或全膝关节置换患者,评估术前使用胰高血糖素样肽-1受体激动剂(GLP-1 RAs)与术后90天再入院及并发症的关联。结果显示GLP-1 RAs组90天再入院几率显著降低(OR 0.73;95%CI 0.64-0.82),其他术后医学并发症无统计学显著差异。作者认为术前GLP-1 RAs使用可能与再入院风险降低相关,无术后医学损害增加的证据,需进一步前瞻性研究验证。
要点
- 术前使用GLP-1 RAs与关节置换术后90天再入院几率降低相关(OR 0.73;95%CI 0.64-0.82)。
- 深静脉血栓、肺栓塞、肺炎、急性肾损伤、手术部位感染、脑血管意外、尿路感染及低血糖事件无统计学显著差异。
- 作者认为术前GLP-1 RAs使用可能与再入院风险降低相关,无术后医学损害增加证据,需进一步前瞻性研究验证。
核心结论
- 术前使用胰高血糖素样肽-1受体激动剂可能与关节置换术后再入院风险降低相关,且无术后医学损害增加的证据。
- 作者认为需进一步前瞻性研究验证这些关联并指导围手术期管理方案。
研究设计与样本
- 系统评价与Meta分析,纳入8项回顾性队列研究,共76091例接受全髋或全膝关节置换的患者。
- 采用随机效应模型计算合并比值比(OR),以考虑研究间变异。
主要发现
- 术前使用GLP-1 RAs组90天再入院几率显著低于对照组(OR 0.73;95%CI 0.64-0.82)。
- 深静脉血栓、肺栓塞、肺炎、急性肾损伤、手术部位感染、脑血管意外、尿路感染及低血糖事件等术后并发症在两组间无统计学显著差异。
- 敏感性分析和剪补法分析显示部分结局存在适度变异,但未实质性改变总体结论。
关键数值与推荐
- 主要结局为术后90天内再入院。
- 其他评估的术后事件包括深静脉血栓、肺栓塞、肺炎、急性肾损伤、手术部位感染、脑血管意外、尿路感染和低血糖事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需进一步前瞻性研究验证这些关联并指导围手术期管理方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Agonists targeting the glucagon-like peptide-1 receptor have gained prominence in treating individuals who have type 2 diabetes and obesity. However, their influence on postoperative medical complications following total joint arthroplasty remains poorly characterized. METHODS: A systematic review and meta-analysis were conducted using data from eight retrospective cohort studies encompassing 76,091 patients who underwent total hip or knee arthroplasty. The primary outcome was hospital readmission within 90 days. Additional postoperative events assessed included deep vein thrombosis, pulmonary embolism, pneumonia, acute kidney injury, surgical site infection, cerebrovascular accident, urinary tract infection, and hypoglycemic event. Pooled odds ratios were calculated using a random-effects model to account for interstudy variability. RESULTS: Patients who received glucagon-like peptide-1 receptor agonists (GLP-1 RAs) before surgery exhibited a significantly lower likelihood of 90-day readmission (odds ratio 0.73; 95% confidence interval: 0.64 to 0.82). There were no statistically significant differences observed in other postoperative medical complications. Sensitivity and trim-and-fill analyses revealed modest variability in select outcomes, but did not substantially alter overall conclusions. CONCLUSIONS: Preoperative glucagon-like peptide-1 receptor agonist use may be linked to reduced readmission risk following joint arthroplasty, without evidence of increased postoperative medical harm. Further prospective studies are warranted to validate these associations and guide perioperative care protocols.
引用
- Chan YC, Chuang SH, Wu LC, et al. Glucagon-Like Peptide-1 Receptor Agonists, Readmission, and Postoperative Complications in Arthroplasty: A Systematic Review and Meta-Analysis. J Arthroplasty. 2025. PMID: 41276236. doi:10.1016/j.arth.2025.11.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。